Novo Nordisk Committed To Advancing In Cardiovascular

Best-known as the world's largest diabetes company, it made sense that Novo Nordisk A/S would increase its research efforts in the cardiovascular space, building on its learnings over the past decade.

So said head of development Martin Holst Lange in an interview with Scrip after the doors closed on the recent European Society of Cardiology meeting. At the congress, held in Barcelona, Novo put the spotlight on ziltivekimab, the lead candidate at US biotech Corvidia Therapeutics, which was acquired by the Danish group in June 2020 for $725m upfront and is the first fully human anti-IL-6 ligand monoclonal antibody